Fortress Biotech (FBIO) Stock Statistics & Valuation Metrics

Fortress Biotech has a market cap or net worth of $95.72M. The enterprise value is -$4.03.

Fortress Biotech has 33,350,994 shares outstanding. The number of shares has decreased by -2.65% in one year.

Fortress Biotech’s return on equity (ROE) is 0.14 and return on invested capital (ROIC) is -49.97%.

The current PE Ratio of Fortress Biotech is 0.9. Fortress Biotech’s PEG ratio is 0.56.

In the last 12 months, Fortress Biotech had revenue of 63.26M and earned 6.82M in profits. Earnings per share was -0.07.

In the last 12 months, operating cash flow was 125.92M and capital expenditures -79.00K, giving a free cash flow of 125.84M billion.

Fortress Biotech pays an annual dividend of ―, resulting in a dividend yield of ―

Fortress Biotech upcoming earnings date is Nov 16, 2026, TBA (Confirmed).

Fortress Biotech as a current ratio of 2.49, with Debt / Equity ratio of 39.47%

In the past 12 months, Fortress Biotech has paid -620.00K in taxes.

Fortress Biotech EV to EBITDA ratio is -4.81, with an EV/FCF ratio of -1.48.

Fortress Biotech has $196.58M in cash and marketable securities with $64.78M in debt, giving a net cash position of $131.79M billion.

Gross margin is 62.53%, with operating margin of -111.00%, and net profit margin of 10.77%.

The average price target for Fortress Biotech is $5.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy